7
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Influenza virus NS1 protein mutations at position 171 impact innate interferon responses by respiratory epithelial cells.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The influenza virus NS1 protein interacts with a wide range of proteins to suppress the host cell immune response and facilitate virus replication. The amino acid sequence of the 2009 pandemic virus NS1 protein differed from sequences of earlier related viruses. The functional impact of these differences has not been fully defined. Therefore, we made mutations to the NS1 protein based on these sequence differences, and assessed the impact of these changes on host cell interferon (IFN) responses. We found that viruses with mutations at position 171 replicated efficiently but did not induce expression of interferon genes as effectively as wild-type viruses in A459 lung epithelial cells. The decreased ability of these NS1 mutant viruses to induce IFN gene and protein expression correlated with decreased activation of STAT1 and lower levels of IFN-stimulated gene (ISG) expression. These findings demonstrate that mutations at position 171 in the NS1 protein result in decreased expression of IFN and ISGs by A549 cells. Consequently, these viruses may be more virulent than the parental strains that do not contain mutations at position 171 in the NS1 protein.

          Related collections

          Author and article information

          Journal
          Virus Res
          Virus research
          Elsevier BV
          1872-7492
          0168-1702
          August 15 2017
          : 240
          Affiliations
          [1 ] Division of Viral Products, Center for Biologics Evaluation and Research, US Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, MD, USA. Electronic address: Ewan.Plant@fda.hhs.gov.
          [2 ] Division of Biotechnology Research and Review II, Center for Drug Evaluation and Research, US Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, MD, USA. Electronic address: Natalia.Ilyushina@fda.hhs.gov.
          [3 ] Division of Biotechnology Research and Review II, Center for Drug Evaluation and Research, US Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, MD, USA. Electronic address: Faruk.Sheikh@fda.hhs.gov.
          [4 ] Division of Biotechnology Research and Review II, Center for Drug Evaluation and Research, US Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, MD, USA. Electronic address: Raymond.Donnelly@fda.hhs.gov.
          [5 ] Division of Viral Products, Center for Biologics Evaluation and Research, US Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, MD, USA. Electronic address: Zhiping.Ye@fda.hhs.gov.
          Article
          S0168-1702(17)30201-0
          10.1016/j.virusres.2017.07.021
          28757142
          13a8c80d-2935-4a5d-85f7-617504dcf786
          Published by Elsevier B.V.
          History

          ISG,A459 cells,Interferon,STAT1,NS1,Influenza
          ISG, A459 cells, Interferon, STAT1, NS1, Influenza

          Comments

          Comment on this article